• Jean-Marc Huët was elected as Chairman of the Board of Directors 
• Shareholders re-elected all members of the Board of Directors standing for re-election
• A dividend of CHF 4.00 per share will be paid out starting from 15 May 2024
• Attending and represented shareholders collectively held a total of 29,994,055 shares, representing 40.28% of the share capital
• Deloitte has been re-elected as auditor for financial year 2025

Basel, Switzerland, 8 May 2024 – Today, Lonza Group Ltd held its Annual General Meeting (AGM), led by the outgoing Chairman of the Board of Directors, Albert M. Baehny. 40.28% of the share capital was represented at the AGM, with attending and represented shareholders collectively holding a total of 29,994,055 shares.

The Board members standing for re-election were all elected for a further term in office of one year. Those standing for re-election included Marion Helmes, Angelica Kohlmann, Christoph Mäder, Roger Nitsch, Barbara Richmond, Jürgen Steinemann and Olivier Verscheure. 

Jean-Marc Huët was elected to the Board of Directors and to the role of Chairman of the Board of Directors for a term of one year. He succeeds Albert M. Baehny, CEO ad interim, who will retire from Lonza in the summer as incoming CEO, Wolfgang Wienand, begins his tenure. The shareholders confirmed Angelica Kohlmann, Christoph Mäder and Jürgen Steinemann as the three members of the Compensation Committee for a further term in office of one year.

The shareholders supported all other motions proposed by the Board of Directors, including the approval of the non-financial report, the remuneration report 2023 (consultative vote) and the binding votes on the compensation for the Board of Directors and the Executive Committee.

Deloitte Ltd, Zurich (CH) was re-elected by shareholders as the auditor for the financial year 2025. 

A dividend of CHF 4.00 per share was proposed by the Board of Directors and approved by the shareholders. The payment period will commence from 15 May 2024. Fifty percent of this dividend will be paid out of the capital contribution reserves and will be exempt from Swiss withholding tax.

For further information please see the .

About Lonza

Lonza is one of the world’s largest healthcare manufacturing organizations. Working across five continents, our global community of around 18,000 colleagues helps pharmaceutical, biotech and nutrition companies to bring their treatments to market. United by our vision to bring any therapy to life, we support our customers with a combination of technological insight, world-class manufacturing, scientific expertise, process excellence and innovation. Our work enables our customers to develop and commercialize their therapeutic discoveries, allowing their patients to benefit from life-saving and life-enhancing treatments.

Our business is structured to meet our customers' complex needs across four divisions: Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients. Our company generated sales of CHF 6.7 billion with a CORE EBITDA of CHF 2.0 billion in Full-Year 2023. Find out more at

Follow @Lonza on
Follow @LonzaGroup on

Lonza Contact Details

Victoria Morgan
Head of External Communications
Lonza Group Ltd
Tel

Daniel Buchta
Investor Relations
Lonza Group Ltd
Tel

Additional Information and Disclaimer
Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.

All trademarks belong to Lonza and are registered in CH, US and/or EU, or belong to their respective third-party owners and are used only for informational purposes.

Privacy Policy